Results 101 to 110 of about 332,508 (311)

Parainfluenza virus 5 genomes are located in viral cytoplasmic bodies whilst the virus dismantles the interferon-induced antiviral state of cells

, 2009
This work was supported by the Wellcome Trust.Although the replication cycle of parainfluenza virus type 5 (PIV5) is initially severely impaired in cells in an interferon (IFN)-induced antiviral state, the virus still targets STAT1 for degradation.
Carlos, T S, Schneider, M, Simas, J P, Randall, Richard Edward, Young, Dan Frushard   +4 more
core   +1 more source

Type I interferons in systemic autoimmunity

Autoimmunity, 2010
Type I IFN (IFN-I) was firstly described in 1957 as a soluble factor responsible for viral resistance in vitro. Today, it is well known that the IFN-I family comprises a wide number of cytokines with different modulatory effects on angiogenesis, cell growth, fibrosis, and apoptosis.
SOZZANI, Silvano, BOSISIO, Daniela, SCARSI, Mirko, TINCANI, Angela   +3 more
openaire   +4 more sources

COVID‐19 Vaccination Is Not Associated With the Development of Idiopathic Inflammatory Myositis in US Veterans

Arthritis Care &Research, EarlyView.
Objective Several case reports have proposed a potential association between COVID‐19 vaccination and the subsequent development of idiopathic inflammatory myositis (IIM). This study examined prior COVID‐19 vaccination in US veterans who developed new‐onset IIM compared to those without new‐onset IIM.
Caleb Hernández, Naomi Schlesinger, Jorge Rojas, Jessica A. Walsh, Tawnie J. Braaten, Gary A. Kunkel, Makoto Jones, Brian C Sauer, Julio Facelli, Grant W. Cannon, Dorota Lebiedz‐Odrobina   +10 more
wiley   +1 more source

Deep sequencing analysis of defective genomes of parainfluenza virus 5 and their role in interferon induction [PDF]

, 2013
This work was supported by The Wellcome Trust (087751/A/08/Z).Preparations of parainfluenza virus 5 (PIV5) that are potent activators of the interferon (IFN) induction cascade were generated by high-multiplicity passage in order to accumulate defective ...
Killip, M. J., Davison, A. J., Young, D.F., Goodbourn, S., Ross, C.S., Young, D. F., Davison, A.J., Short, J.A.L., Ross, C. S., Randall, R. E., Gatherer, D., Short, J. A. L., Killip, M.J., Randall, R.E.   +13 more
core   +1 more source

Type I interferon pathway genetic variants in severe COVID-19

Virus Research
Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by SARS-CoV-2. According to the World Health Organization (WHO), there have been over 760 million reported cases and over 6 million deaths caused by this disease worldwide.
A.F.L. Montenegro, M.A.F. Clementino, J.N.U. Yaochite   +2 more
doaj   +1 more source

Artificial Intelligence in Systemic Sclerosis: Clinical Applications, Challenges, and Future Directions

Arthritis Care &Research, EarlyView.
Systemic sclerosis (SSc) is a rare autoimmune disease defined by immune dysregulation, vasculopathy, and progressive fibrosis of the skin and internal organs. Despite advances in care, major complications such as interstitial lung disease (ILD) and myocardial involvement remain the leading causes of morbidity and mortality.
Cristiana Sieiro Santos, José Miguel Sequí‐Sabater, Diego Benavent   +2 more
wiley   +1 more source

Mumps virus Enders strain is sensitive to interferon (IFN) despite encoding a functional IFN antagonist

, 2009
Although the Enders strain of mumps virus (MuV) encodes a functional V protein that acts as an interferon (IFN) antagonist, in multi-cycle growth assays MuV Enders grew poorly in naive ('IFN-competent' Hep2) cells but grew to high titres in 'IFN ...
Rima, B K, Andrejeva, Jelena, K. Lemon, B. K. Rima, Duprex, P, W. P. Duprex, M. C. Galiano, Galiano, M, J. Andrejeva, D. F. Young, R. E. Randall, Young, D F, Lemon, K, Chen, Y-H, Y.-H. Chen, Randall, Richard Edward   +15 more
core   +1 more source

A novel broad-spectrum treatment for respiratory virus infections : influenza-based defective interfering virus provides protection against pneumovirus infection in vivo [PDF]

, 2011
Respiratory viruses represent a major clinical burden. Few vaccines and antivirals are available, and the rapid appearance of resistant viruses is a cause for concern.
Edworthy, Nicole Lynn, Nicole L. Edworthy, Andrew J. Easton, Meng, Bo, Easton, A. J. (Andrew J.), Bo Meng, Scott, P. D. (Paul D.), Marriott, Anthony C., Anthony C. Marriott, Nigel J. Dimmock, Dimmock, N. J., Paul D. Scott   +11 more
core   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study from the EUSTAR Cohort

Arthritis Care &Research, Accepted Article.
Objective JAK inhibitors (JAKis) have shown promising effects in early‐phase studies of SSc. We aimed to assess the safety and explore effectiveness of JAKis compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the EUSTAR cohort was performed.
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P Denton, Madelon C Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Biophysical investigation of the ligand-induced assembling of the human type I interferon receptor

, 2005
Type I interferons (IFNs) elicit antiviral, antiproliferative and immunmodulatory responses through binding to a shared receptor consisting of the transmembrane proteins ifnar1 and ifnar2.
Lamken, Peter
core